Term ends Sep 5, 2034 · High confidence
20-year base term ends Sep 5, 2034
Held by Ellodi Pharmaceuticals, L.P.
Filed Mar 7, 2016 as application 14/917,125 · Granted Nov 12, 2019
Base term, 20 years from filing
Today
2014
2034
Clock starts
Sep 5, 2014
Sep 5, 2014
Term ends
Sep 5, 2034
Sep 5, 2034
Granted
Nov 12, 2019
Nov 12, 2019
base term
fee events
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
None
Term adjustment
No prosecution delay on this record.
None
Terminal disclaimer
No disclaimer on this record.
1 of 3
Maintenance fees paid
Three maintenance fees fall due, at 3.5, 7.5 and 11.5 years from grant. This counts the ones the record shows paid.
12
Family applications on record here
Applications sharing this one's continuity chain whose file history this site holds. The family may have others.
This patent's term is its 20-year base term, with no adjustment for prosecution delay. 1 of 3 maintenance fees is paid so far. Confidence: High. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Sep 5, 2014, when application PCT/US2014/054203, the earliest non-provisional in its chain, was filed (this one was filed Mar 7, 2016) | Sep 5, 2034 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | None on record | no cap applied | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 1 of 3 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | Sep 5, 2034 | High confidence |
This family
| US 9,782,312 | In force Sep 2034 | Sep 2034 |
| Application PCT/US2014/054023 | PCT application no patent term | no patent term |
| US 10,471,071 | this patent Sep 2034 | Sep 2034 |
| Application 29/621,469 | Abandoned not computed | not computed |
| US 11,166,961 | In force Sep 2034 | Sep 2034 |
| US D904,073 | In force Dec 2035 | Dec 2035 |
| US 11,260,061 | In force Sep 2034 | Sep 2034 |
| US 12,310,976 | In force Sep 2034 | Sep 2034 |
8 of 12 applications in this family shown, earliest filings first. The applications whose file history this site holds. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Jul 11, 2017 Reel 42976, frame 9 | Gosselin, Michael A.; Lai, Jin-wang; Venkatesh, Gopi M. | Aptalis Pharmatech Inc. | Assignment of Assignor's Interest |
| Dec 4, 2018 Reel 47672, frame 450 | Adare Pharmaceuticals, Inc. | Adare Development I, L.P, | Assignment of Assignor's Interest |
| Dec 18, 2018 Reel 47807, frame 967 | Adare Development I, L.p. | Bank of Montreal | Security Interest |
| Sep 5, 2019 Reel 50278, frame 483 | Aptalis Pharmatech, Inc. | Adare Pharmaceuticals, Inc. | Change of Name |
| Jul 16, 2020 Reel 53231, frame 843 | Adare Development I, L.p. | Adare Pharmaceuticals US, L.P. | Change of Name |
| Sep 22, 2020 Reel 53852, frame 697 | Bank Of Montreal, As Collateral Agent | Adare Pharmaceuticals, Inc.; Adare Development I, L.p.; Adare Pharmaceuticals USA, Inc. | Release of Security Interest Recorded at Reel/Frames 037246/0313, 047807/0967, 053474/0276 |
| Sep 22, 2020 reel/frame not recorded | Bank Of Montreal, As Collateral Agent | Adare Pharmaceuticals, Inc. | Release of Security Interest Recorded at Reel/Frames 037246/0313, 047807/0967, 053474/0276 |
| Sep 22, 2020 reel/frame not recorded | Bank Of Montreal, As Collateral Agent | Adare Development I, L.p. | Release of Security Interest Recorded at Reel/Frames 037246/0313, 047807/0967, 053474/0276 |
| Sep 22, 2020 reel/frame not recorded | Bank Of Montreal, As Collateral Agent | Adare Pharmaceuticals USA, Inc. | Release of Security Interest Recorded at Reel/Frames 037246/0313, 047807/0967, 053474/0276 |
| May 21, 2024 Reel 67487, frame 177 | Adare Pharmaceuticals US, L.P. | Ellodi Pharmaceuticals, L.p. | Change of Name |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
What's changing
Sep 2034
Term ends Sep 5, 2034. Maintenance fees still fall due before then
Citations
31
later US patents cite this one
That is top 10% of utility patents granted in 2019 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.